Journal article
Health care resource utilization and associated costs among metastatic cutaneousmelanoma patients treated with ipilimumab (INTUITION Study)
GA McArthur, P Mohr, PA Ascierto, A Arance, AB Hernaez, P Kaskel, M Weichenthal, R Shinde, K Stevinson
Oncologist | WILEY | Published : 2017
Abstract
Background. There are limited real-world data on health care resource utilization (HCRU) among advanced melanoma patients. The objective of this study was to describe HCRU and health care costs associated with the management of advanced melanoma patients receiving ipilimumab. Methods. This retrospective multinational, observational study included advanced melanoma patients from Australia, Germany, Italy, and Spain who had received at least 1 dose of ipilimumab. Data extracted from medical charts included inpatient admissions, outpatient visits, surgical procedures, laboratory investigations, radiation therapy, imaging studies, and concomitant medications. Cost estimates were based on unit co..
View full abstractGrants
Funding Acknowledgements
The following contributors are acknowledged: Francois Bourhis for programming support; Dr. Matthias Hunger of the Mapi Group for programming support and writing assistance, which was funded by Merck & Co.; and the following site investigators for data acquisition: Dr. Georgina Long, Dr. Victoria Atkinson, Dr. Matteo Carlino, Prof. Dirk Schadendorf, Prof. Dr. Claus Garbe, Prof. Dr. Jochen Utikal, Dr. Vanna Chiarion-Sileni, Dr. Michele Maio, Dr. Paola Queirolo, Dr. Michele Guida, Dr. Enrique Espinosa Arranz, Dr. Eva Munoz Couselo, Dr. Delvys Rodriguez Abreu, and Dr. Sara Esperanza Arriola Arellano.